{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:12:00Z","timestamp":1792613520430,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":1351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajp.amjpathol.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ajpath.2015.11.011","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T13:24:30Z","timestamp":1458566670000},"page":"733-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":864,"title":["The Dualistic Model of Ovarian Carcinogenesis"],"prefix":"10.1016","volume":"186","author":[{"given":"Robert J.","family":"Kurman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ie-Ming","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2015.11.011_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/AOG.0b013e3181e7961d","article-title":"Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary","volume":"116","author":"Schmeler","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib3","series-title":"WHO classification of tumours of female reproductive organs","author":"Kurman","year":"2014"},{"key":"10.1016\/j.ajpath.2015.11.011_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/PGP.0000000000000266","article-title":"Seromucinous tumors of the ovary. What's in a name?","volume":"35","author":"Kurman","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1097\/PAS.0000000000000476","article-title":"Morphologic and molecular characteristics of mixed epithelial ovarian cancers","volume":"39","author":"Mackenzie","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib6","series-title":"Blaustein's Pathology of the Female Genital Tract","first-page":"679","article-title":"Surface epithelial tumors of the ovary","author":"Seidman","year":"2011"},{"key":"10.1016\/j.ajpath.2015.11.011_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4293","article-title":"Shih IeM: Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants","volume":"232","author":"Ardighieri","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","article-title":"Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up","volume":"29","author":"Longacre","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2007.01.030","article-title":"Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma","volume":"105","author":"Shvartsman","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PAS.0b013e31802cbbe9","article-title":"The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis","volume":"31","author":"Dehari","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/path.4252","article-title":"KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma","volume":"231","author":"Tsang","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib14","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/PAS.0000000000000313","article-title":"BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors","volume":"38","author":"Zeppernick","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/PAS.0000000000000155","article-title":"Evaluation of microinvasion and lymph node involvement in ovarian serous borderline\/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases","volume":"38","author":"Maniar","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e318229449f","article-title":"Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis","volume":"35","author":"Kurman","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2007.02.016","article-title":"Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt\/beta-catenin and PI3K\/Pten signaling pathways","volume":"11","author":"Wu","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2015.11.011_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1054\/bjoc.2000.1581","article-title":"beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis","volume":"84","author":"Saegusa","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib19","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.humpath.2004.07.019","article-title":"Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas","volume":"35","author":"Catasus","year":"2004","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4161\/cbt.5.7.2751","article-title":"Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms","volume":"5","author":"Nakayama","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ajpath.2015.11.011_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2015.11.011_bib22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ygyno.2006.05.029","article-title":"KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants","volume":"103","author":"Mayr","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.humpath.2006.10.007","article-title":"Alternate molecular genetic pathways in ovarian carcinomas of common histological types","volume":"38","author":"Willner","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju146","article-title":"Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis","volume":"106","author":"Guan","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2015.11.011_bib25","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1038\/ncomms7118","article-title":"Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling","volume":"6","author":"Chandler","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2015.11.011_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ijc.28701","article-title":"Epigenetic determinants of ovarian clear cell carcinoma biology","volume":"135","author":"Yamaguchi","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/PGP.0b013e31823f8482","article-title":"Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A","volume":"31","author":"Wu","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12885-015-1421-8","article-title":"Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms","volume":"15","author":"Mackenzie","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/path.4134","article-title":"RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary","volume":"229","author":"Ryland","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PGP.0b013e3181f45f3e","article-title":"The origin of ovarian carcinomas: a unifying hypothesis","volume":"30","author":"Auersperg","year":"2011","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.humpath.2015.03.017","article-title":"PAX8 expression in ovarian surface epithelial cells","volume":"46","author":"Adler","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/PAS.0000000000000166","article-title":"Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma","volume":"38","author":"Kuhn","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAS.0000000000000369","article-title":"Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib35","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1158\/1055-9965.EPI-13-0391","article-title":"Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium","volume":"22","author":"Kobel","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajpath.2015.11.011_bib36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ajcp\/93.4.457","article-title":"Ovarian carcinomas with transitional cell carcinoma pattern","volume":"93","author":"Silva","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2015.11.011_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2015.11.011_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PGP.0000000000000207","article-title":"Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking tp53 mutations in the Cancer Genome Atlas Ovarian Study","volume":"35","author":"Vang","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib40","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib41","doi-asserted-by":"crossref","first-page":"e18064","DOI":"10.1371\/journal.pone.0018064","article-title":"Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers","volume":"6","author":"Helland","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2015.11.011_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2015.11.011_bib43","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1158\/1078-0432.CCR-13-0066","article-title":"Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations","volume":"19","author":"George","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.pgp.0000092134.88121.56","article-title":"Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis","volume":"22","author":"Jin","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1096-9896(199712)183:4<424::AID-PATH949>3.0.CO;2-L","article-title":"Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours","volume":"183","author":"Abeln","year":"1997","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2015.11.011_bib47","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/0008-5472.CAN-08-3913","article-title":"Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas","volume":"69","author":"Kuo","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib48","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1158\/0008-5472.CAN-04-3625","article-title":"Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations","volume":"65","author":"Pohl","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib50","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-14-1292","article-title":"Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver","volume":"20","author":"Emmanuel","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib51","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-04-2067","article-title":"Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors","volume":"64","author":"Ho","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib52","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ajpath.2011.11.026","article-title":"Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells","volume":"180","author":"Sheu","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4293","article-title":"Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants","volume":"232","author":"Ardighieri","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1101\/gad.1516407","article-title":"A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors","volume":"21","author":"Dankort","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.ajpath.2015.11.011_bib55","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/onc.2009.106","article-title":"The mir-34 microRNA is required for the DNA damage response in\u00a0vivo in C. elegans and\u00a0in\u00a0vitro in human breast cancer cells","volume":"28","author":"Kato","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2015.11.011_bib56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/PGP.0b013e3181ed89b3","article-title":"Loss of p16INK4A expression in low-grade ovarian serous carcinomas","volume":"30","author":"Schlosshauer","year":"2011","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib57","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2015.11.011_bib58","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1097\/IGC.0b013e31826b5dcc","article-title":"Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma","volume":"22","author":"Ayhan","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib59","first-page":"7052","article-title":"Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary","volume":"60","author":"Sato","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib60","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/00000478-200212000-00001","article-title":"Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas","volume":"26","author":"Shappell","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.pgp.0000177125.31046.fd","article-title":"Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive","volume":"25","author":"Vang","year":"2006","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib62","first-page":"1489","article-title":"Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy","volume":"53","author":"Mok","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib63","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T","article-title":"K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases","volume":"79","author":"Cuatrecasas","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib64","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.5858\/132.11.1753","article-title":"Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors","volume":"132","author":"Seidman","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2015.11.011_bib65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/path.4572","article-title":"Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin","volume":"237","author":"Wang","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib66","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib67","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0140-6736(01)05992-X","article-title":"Tubal ligation and risk of ovarian cancer","volume":"358","author":"Piek","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2015.11.011_bib68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0090-8258(03)00365-2","article-title":"BRCA1\/2-related ovarian cancers are of tubal origin: a hypothesis","volume":"90","author":"Piek","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ajpath.2015.11.011_bib70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib71","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib72","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0b013e3181ef7b16","article-title":"Are all pelvic (nonuterine) serous carcinomas of tubal origin?","volume":"34","author":"Przybycin","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib73","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0000000000000352","article-title":"Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series","volume":"39","author":"Morrison","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAS.0000000000000353","article-title":"Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas","volume":"39","author":"Gilks","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib75","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/IGC.0b013e3181a1b5dc","article-title":"High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy","volume":"19","author":"Hirst","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib76","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/PAS.0000000000000199","article-title":"Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery","volume":"38","author":"Rabban","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib77","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PGP.0b013e31822ea955","article-title":"Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases","volume":"31","author":"Tang","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib78","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma (STIC) and concurrent pelvic high-grade serous carcinoma- evidence supporting their clonal relationship","volume":"226","author":"Kuhn","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib79","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/PAS.0b013e3181dcede7","article-title":"Shih Ie-M: Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis","volume":"34","author":"Kuhn","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib80","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2015.11.011_bib81","first-page":"107","article-title":"Ovarian cancer risk after salpingectomy: a nationwide population-based study","author":"Falconer","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2015.11.011_bib82","doi-asserted-by":"crossref","first-page":"471.e1","DOI":"10.1016\/j.ajog.2014.01.003","article-title":"Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention","volume":"210","author":"McAlpine","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib83","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/PAS.0b013e31822f58bc","article-title":"Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study","volume":"35","author":"Visvanathan","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","article-title":"Serous carcinogenesis in the fallopian tube: a descriptive classification","volume":"27","author":"Jarboe","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib85","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/modpathol.2011.12","article-title":"Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis","volume":"24","author":"Espinosa","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib86","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2004.11.053","article-title":"Malignant mixed Mullerian tumor of the fimbriated end of the fallopian tube: origin as an intraepithelial carcinoma","volume":"97","author":"Gagner","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib87","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2015.11.011_bib88","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ajpath.2015.11.011_bib89","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study","volume":"111","author":"Kobel","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib90","doi-asserted-by":"crossref","first-page":"167ra4","DOI":"10.1126\/scitranslmed.3004952","article-title":"Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers","volume":"5","author":"Kinde","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajpath.2015.11.011_bib91","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/PAS.0b013e318282da7f","article-title":"Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis","volume":"37","author":"Bijron","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib92","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ajog.2005.01.041","article-title":"The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer","volume":"192","author":"Fishman","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib93","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2013.01.029","article-title":"Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy","volume":"129","author":"Powell","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib94","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2013.12.009","article-title":"Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations","volume":"132","author":"Conner","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib95","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib96","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/IGC.0b013e3182a80ac8","article-title":"Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)","volume":"23","author":"Wethington","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajpath.2015.11.011_bib97","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2015.11.011_bib98","doi-asserted-by":"crossref","first-page":"e104521","DOI":"10.1371\/journal.pone.0104521","article-title":"Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis","volume":"9","author":"Habis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2015.11.011_bib99","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-14-3368","article-title":"Mevalonate pathway antagonist suppresses formation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models","volume":"21","author":"Kobayashi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2015.11.011_bib100","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2015.11.011_bib101","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2015.11.011_bib102","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2015.11.011_bib103","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2015.11.011_bib104","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944016000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944016000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:08:50Z","timestamp":1615939730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944016000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0002944016000080"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.011","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Dualistic Model of Ovarian Carcinogenesis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}